Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company’s Novel Adjuvanted Recombinant Shingles Vaccine REC610

PR Newswire
February 13, 2023 — 15:02 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: China Covid-19 finance healthcare Hong Kong investment jiangsu Joint venture medicine stock exchange technology Vaccine

Related News:

Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever

April 24, 2024 — 13:00

Zepp Health Corporation Files 2023 Annual Report on Form 20-F

April 23, 2024 — 20:20

TTC Announces Strategic Expansion into Western Australia with New Perth Office

April 23, 2024 — 04:00

Tantech Holdings Ltd Announces $2.1 Million Private Placement

April 23, 2024 — 03:58

Latham Adds Experienced M&A Partner in Tokyo

April 23, 2024 — 03:15

DFI and Outdoor LCD Manufacturer ODHitec Introduce Charging Station Solutions at EVS37

April 22, 2024 — 10:00

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

April 22, 2024 — 09:53

Mayur achieves major milestone with US$155 million for Central Lime Project in Papua New Guinea

April 22, 2024 — 09:38

Flash News: OKX Wallet Integrates with Pac Finance for Enhanced DeFi Access

April 21, 2024 — 17:00